Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT Jan 27, 2025
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Jan 23, 2025
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease Jan 06, 2025
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Nov 14, 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Nov 14, 2024
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Nov 12, 2024
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Nov 12, 2024
